A biomarker to differentiate between primary and cocaine-induced major depression in cocaine use disorder: The role of platelet IRAS/nischarin (I<inf>1</inf>-imidazoline receptor)

Benjamin Keller, Joan Ignasi Mestre-Pinto, María álvaro-Bartolomé, Diana Martinez-Sanvisens, Magí Farre, M. Julia García-Fuster, Jesús A. García-Sevilla, Marta Torrens, F. Fonseca, J. Mateus, E. Papaseit, C. Pérez-Mañá, R. Rodríguez-Minguela, P. Rossi, C. Tamarit, G. Vallecillo

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

Abstract

© 2017 Keller, Mestre-Pinto, álvaro-Bartolomé, Martinez-Sanvisens, Farre, García-Fuster, García-Sevilla and Torrens. The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were assessed by Western blot in subjects with CUD and primary MDD (n = 16) or CUD-induced MDD (n = 9; antidepressant free, AD-; antidepressant treated, AD+) and controls (n = 10) at basal level and/or after acute tryptophan depletion (ATD). Basal platelet 5-HT2A receptor (monomer) was reduced in comorbid CUD/MDD subjects (all patients: 43%) compared to healthy controls, and this down-regulation was independent of AD medication (decreases in AD-: 47%, and in AD+: 40%). No basal differences were found for IRAS/nischarin contents in AD+ and AD- comorbid CUD/MDD subjects. The comparison of IRAS/nischarin in the different subject groups during/after ATD showed opposite modulations (i.e., increases and decreases) in response to low plasma tryptophan levels with significant differences discriminating between the subgroups of CUD with primary MDD and CUD-induced MDD. These specific alterations suggested that platelet IRAS/nischarin might be useful as a biomarker to discriminate between primary and CUD-induced MDD in this dual pathology.
Original languageEnglish
Article number258
JournalFrontiers in Psychiatry
Volume8
Issue numberDEC
DOIs
Publication statusPublished - 1 Dec 2017

Keywords

  • Acute tryptophan depletion
  • Antidepressant drugs
  • Cocaine use disorder
  • Cocaine-induced depression
  • IRAS/nischarin
  • Major depressive disorder
  • Platelet biomarker

Fingerprint Dive into the research topics of 'A biomarker to differentiate between primary and cocaine-induced major depression in cocaine use disorder: The role of platelet IRAS/nischarin (I<inf>1</inf>-imidazoline receptor)'. Together they form a unique fingerprint.

Cite this